News

October 14, 2016

Report on Mesothelioma Immunotherapy Suggests Future in Combination Approaches

News

Studies in immune checkpoint blockade against malignant mesothelioma have delivered disappointing results, leading experts to suggest that the future of mesothelioma treatment rests in combination approaches, including immunotherapies and traditional treatments. An extensive ... Read more

October 13, 2016

Scientists Find New Mechanism that May Help Develop Therapies Targeting Mesothelioma

News

Researchers have identified a novel mechanism that stimulates the death of malignant pleural mesothelioma (MPM) cells, providing potential therapeutic targets for the treatment of this aggressive disease. The study, “MicroRNA-302b ... Read more

October 12, 2016October 12, 2016

Two Therapies Show Early Promise as Treatment for Pleural Mesothelioma

News

Researchers at Hyogo College of Medicine in Japan recently reviewed the therapeutic agents suitable for the treatment of malignant pleural mesothelioma (MPM) and propose that an anti-CD26 monoclonal antibody and ... Read more

October 11, 2016

Measuring MicroRNAs in Blood May Help Diagnose Mesothelioma, Study Finds

News

Diagnosing and managing malignant pleural mesothelioma (MPM) may soon be performed using a simple blood test, a new study suggests, showing that measuring the levels of specific microRNAs in the ... Read more

October 10, 2016

Features Linked to Drug Resistance of Epithelial Mesothelioma Are Identified

News

The epithelial variant of malignant peritoneal mesothelioma is characterized by molecular changes that give stem cell properties to the cancer cells and promote resistance to cancer drugs, according to a ... Read more

October 7, 2016

DNA Repair Genes May Predict Response to Chemotherapy in Mesothelioma Patients, Study Finds

News

DNA damage response plays a crucial role in response to platinum-based chemotherapy regimens, which are often used to treat malignant pleural mesothelioma (MPM). Now, researchers have identified several key genes known ... Read more

October 7, 2016

Types of Mesothelioma Clinical Trials

News

The decision to enroll in a clinical trial should involve a discussion between the person with mesothelioma and that individual’s physician. Participation in a trial will depend on many factors, including the ... Read more

October 6, 2016October 6, 2016

Argenx Wins Frost & Sullivan Award for Antibody Platform Aiming to Treat Mesothelioma and Other Cancers

News

The 2016 European Frost & Sullivan Award for Technology Innovation, recognizing excellence in the therapeutic antibody engineering market, was recently awarded to Argenx, a company based in the Netherlands that is developing multiple drug candidates, ... Read more

October 5, 2016

Rosetta Receives 2 Patent Allowances, 1 for Mesothelioma Diagnostic

News

Rosetta Genomics, a company that develops microRNA-based diagnostics, has added two new patent allowances to its intellectual property. A patent allowance is issued by a regulatory entity (U.S. Patent and ... Read more

October 4, 2016October 5, 2016

Trial Seeks Patients With Inoperable Malignant Pleural Mesothelioma

News

Boehringer Ingelheim is enrolling patients with inoperable malignant pleural mesothelioma (MPM) into a Phase 2/3 trial evaluating the effectiveness of nintedanib in combination with Alimta (pemetrexed) and Platinol (cisplatin), followed by ... Read more